En Español
Semaglutide vs. tirzepatide

Wegovy vs. Zepbound: Which One Fits You? (2026 Comparison)

Wegovy vs Zepbound compared: active ingredients, FDA approvals, trial data, side effects, what affects cost and how to get either one through an online visit.

Medically reviewed by the Forever Health Rx medical team
Last reviewed September 23, 2026

A man with a backpack walking through a leafy city park

Wegovy vs Zepbound is the brand-level version of a bigger question: semaglutide or tirzepatide? Both are FDA-approved for chronic weight management and available as once-weekly injections (Wegovy is also approved as a once-daily tablet), and both were tested in large clinical trials. Here is how they compare, and how to get either one through a licensed provider online.

Key takeaways

  • Wegovy® is semaglutide, made by Novo Nordisk; Zepbound® is tirzepatide, made by Eli Lilly.
  • Both are FDA-approved for chronic weight management; Wegovy is also approved for cardiovascular risk reduction and MASH, and Zepbound for obstructive sleep apnea.
  • In the SURMOUNT-5 head-to-head trial (2025), average weight loss was higher with Zepbound than with Wegovy, though individual results vary.
  • Side effects are mostly digestive and similar for both, and both carry the same boxed warning about thyroid C-cell tumors.
  • A licensed provider decides which medication, if any, is appropriate for you; a prescription is never guaranteed.

Wegovy vs Zepbound at a glance

Wegovy® Zepbound®
Active ingredient Semaglutide Tirzepatide
Mechanism GLP-1 receptor agonist Dual GIP and GLP-1 receptor agonist
Manufacturer Novo Nordisk Eli Lilly
FDA approval for weight management June 2021 November 2023
Additional FDA-approved uses Cardiovascular risk reduction (2024); MASH, a form of fatty liver disease (2025) Moderate to severe obstructive sleep apnea in adults with obesity (2024)
How it is taken Once-weekly injection (pen); a once-daily tablet was approved in late 2025 Once-weekly injection (pen or vial)
Key placebo-controlled trial STEP 1: about 14.9% average weight reduction at 68 weeks (placebo about 2.4%) SURMOUNT-1: about 15.0% to 20.9% average weight reduction at 72 weeks, by dose (placebo about 3.1%)
Head-to-head (SURMOUNT-5, 72 weeks) About 13.7% average weight reduction About 20.2% average weight reduction
Most common side effects Nausea, diarrhea, vomiting, constipation, abdominal pain Nausea, diarrhea, vomiting, constipation, abdominal pain

Trial figures are averages from specific study populations, not a prediction for you; individual results vary. For prices, see our GLP-1 cost guide. Brand names are trademarks of their respective owners; Forever Health Rx is not affiliated with them.

What each medication is

Wegovy contains semaglutide, a GLP-1 receptor agonist. It mimics a gut hormone that signals fullness, slows stomach emptying and helps regulate blood sugar. The FDA approved Wegovy for chronic weight management in June 2021; later approvals added cardiovascular risk reduction in adults with heart disease and obesity or overweight (March 2024) and MASH, a serious form of fatty liver disease (2025).

Zepbound contains tirzepatide, a dual GIP and GLP-1 receptor agonist. It activates the same GLP-1 receptor as semaglutide plus a second hormone receptor, GIP. The FDA approved Zepbound for chronic weight management in November 2023 and, in December 2024, for moderate to severe obstructive sleep apnea in adults with obesity.

The same 2 molecules are sold as Ozempic® (semaglutide) and Mounjaro® (tirzepatide) for type 2 diabetes; those products are not FDA-approved for weight management. For the molecule-level comparison, read our pillar guide on semaglutide vs tirzepatide.

How they are taken

Both medications are injected once a week under the skin. Both start at a low dose that the provider increases gradually over several months, and your provider sets that schedule.

Wegovy injection comes in pre-filled pens, and the FDA also approved a once-daily Wegovy tablet in late 2025; availability and coverage can differ between forms. Zepbound comes in pre-filled pens and in vials. Your provider and pharmacy explain how to use the form you are prescribed.

Wegovy vs Zepbound: what the trials showed

Each earned approval through a large placebo-controlled trial; in 2025, a head-to-head trial compared them directly.

STEP 1 (Wegovy). In this 68-week trial of 1,961 adults with obesity or overweight and without diabetes, the average change in body weight was about -14.9% with the weight-management dose of semaglutide plus lifestyle intervention, versus about -2.4% on placebo.

SURMOUNT-1 (Zepbound). In this 72-week trial of 2,539 adults with obesity or overweight and without diabetes, the average change in body weight was about -15.0%, -19.5% and -20.9% across the 3 tirzepatide doses studied, versus about -3.1% on placebo.

SURMOUNT-5 (head to head). This 72-week trial randomly assigned 751 adults with obesity and without type 2 diabetes to tirzepatide or semaglutide at the highest tolerated dose. The average change in body weight was about -20.2% with tirzepatide and about -13.7% with semaglutide. The trial was funded by Eli Lilly and was open-label.

The head-to-head numbers favor Zepbound on average, but an average does not predict what will happen for any one person. Which one may suit you depends on your health history and tolerance.

Side effects to expect

The side effect profiles of Wegovy and Zepbound are more similar than different. The most common side effects in the prescribing information for both include nausea, diarrhea, vomiting, constipation, abdominal pain and indigestion. Both labels note these were reported most often while the dose was being increased, and the Zepbound label notes they decreased over time.

Both carry a boxed warning about a possible risk of thyroid C-cell tumors, based on rodent studies, and neither should be used by anyone with a personal or family history of medullary thyroid carcinoma or MEN 2. Both labels also warn about pancreatitis, gallbladder problems, low blood sugar (especially with insulin or sulfonylureas), kidney injury from dehydration, serious allergic reactions, severe digestive side effects and aspiration during general anesthesia or deep sedation. In January 2026, the FDA said its evaluation did not identify an increased risk of suicidal thoughts or behavior with GLP-1 medications and asked for that warning to be removed; it still advises telling your health care professional about new or worsening depression or suicidal thoughts.

When to seek care. Contact your provider right away for severe abdominal pain that does not go away, yellowing of the skin or eyes, vision changes, or signs of low blood sugar. Call 911 for trouble breathing, swelling of the face or throat, thoughts of harming yourself, or any emergency. Side effects can be reported to the FDA MedWatch program at 1-800-FDA-1088.

See is tirzepatide safe?, semaglutide side effects and the full safety information on our semaglutide page and tirzepatide page.

What Wegovy and Zepbound cost

Both manufacturers publish list prices and run self-pay programs (NovoCare for Wegovy, LillyDirect for Zepbound). These prices change often, so check the manufacturer's own site for the current figure; our guide on how much GLP-1 medication costs online lists the manufacturer prices we could verify, with the date we checked.

Insurance coverage varies by plan. Many plans require prior authorization or exclude weight-management medications, and coverage can also depend on the reason the medication is prescribed, so ask your plan.

Forever Health Rx pricing is listed on the semaglutide and tirzepatide treatment pages. The online visit is free, and submitting a visit does not guarantee a prescription.

How to get Wegovy or Zepbound online

Both are prescription-only, so the route is a licensed provider who reviews your health history and decides whether the medication is appropriate. Forever Health Rx is a telemedicine platform that connects adults with licensed providers for this evaluation; if a medication is prescribed, it ships from a licensed US pharmacy.

Generally, both medications are indicated for adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition such as high blood pressure, type 2 diabetes or high cholesterol, as determined by a licensed provider after reviewing your health history. BMI is a screening measure, not a diagnosis. If a medication fits, the provider chooses between semaglutide and tirzepatide with you, based on your conditions, prior experience, tolerance and budget. Not sure yet? Read am I a candidate for GLP-1?.

A prescription is never guaranteed, and switching between the 2 medications later is also a provider decision. Learn what happens in your online visit, or start your health assessment today.

About compounded medications. Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness or quality before they are marketed. FDA-approved and compounded medications are not the same. Brand names are trademarks of their respective owners; Forever Health Rx is not affiliated with them.

Talk it through with a licensed provider

Your evaluation is 100% online. A licensed provider reviews your health history and decides whether treatment is medically appropriate. Submitting an evaluation does not guarantee a prescription.

Start your health assessment

Important Safety Information: Semaglutide Tirzepatide

Frequently asked questions

Is Zepbound better than Wegovy for weight loss?

On average, in the SURMOUNT-5 head-to-head trial, yes. The average change in body weight over 72 weeks was about -20.2% with tirzepatide versus about -13.7% with semaglutide. Those are study averages; individual results vary widely, and a provider considers far more than the average.

Are Wegovy and Zepbound the same as Ozempic and Mounjaro?

They contain the same active ingredients but are different products. Ozempic (semaglutide) and Mounjaro (tirzepatide) are FDA-approved for type 2 diabetes. Wegovy and Zepbound are the versions FDA-approved for chronic weight management.

Can I take Wegovy and Zepbound together?

No. Both labels advise against combining them with other GLP-1 medications. If your provider changes your medication, they manage the switch; do not combine or self-adjust.

Is compounded semaglutide or tirzepatide the same as Wegovy or Zepbound?

No. Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness or quality. They are not the same as the FDA-approved products Wegovy® and Zepbound®, and they are not generic versions of them.

Sources

  1. WEGOVY (semaglutide) injection and tablets — Prescribing Information. DailyMed, U.S. National Library of Medicine. Accessed September 23, 2026.
  2. ZEPBOUND (tirzepatide) injection — Prescribing Information. DailyMed, U.S. National Library of Medicine. Accessed September 23, 2026.
  3. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. New England Journal of Medicine (PubMed 33567185). Accessed September 23, 2026.
  4. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. New England Journal of Medicine (PubMed 35658024). Accessed September 23, 2026.
  5. Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. 2025;393(1):26-36. New England Journal of Medicine (PubMed 40353578). Accessed September 23, 2026.
  6. June 2021 Office of Women's Health e-Update (FDA approval of Wegovy for chronic weight management). U.S. Food and Drug Administration, June 2021. Accessed September 23, 2026.
  7. FDA Approves New Medication for Chronic Weight Management (Zepbound). U.S. Food and Drug Administration, November 8, 2023. Accessed September 23, 2026.
  8. FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight. U.S. Food and Drug Administration, March 8, 2024. Accessed September 23, 2026.
  9. FDA Approves First Medication for Obstructive Sleep Apnea. U.S. Food and Drug Administration, December 20, 2024. Accessed September 23, 2026.
  10. FDA Approves Treatment for Serious Liver Disease Known as 'MASH'. U.S. Food and Drug Administration, August 15, 2025. Accessed September 23, 2026.
  11. FDA Requests Removal of Suicidal Behavior and Ideation Warning from GLP-1 RA Medications. U.S. Food and Drug Administration, January 13, 2026. Accessed September 23, 2026.
  12. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. U.S. Food and Drug Administration. Accessed September 23, 2026.

Forever Health Rx does not provide emergency medical care. Call 911 or go to the nearest emergency department if you are experiencing a medical emergency. For urgent questions about a serious side effect, message your care team through the patient portal and seek in-person care if symptoms are severe.

Not medical advice. Results may vary. This article is for general education and does not replace a consultation with a licensed healthcare provider. To report a side effect, contact your provider through the patient portal or FDA MedWatch at 1-800-FDA-1088 (www.fda.gov/medwatch).